



Attorney Docket No.: 6297.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jorgensen et. al.

Serial No.: 10/721,961

Group Art Unit: To be assigned

Filed: November 25, 2003

Examiner: To be assigned

For: Kunitz-Type Sequences and Polypeptides

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References (17)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on **March 31, 2004**

Dolly Kapadia
(name of person mailing paper)

Dolly Kapadia
(signature of person mailing paper)



Attorney Docket No.: 6297.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jorgensen et. al.

Application No.: 10/721,961

Group Art Unit: To be assigned

Filed: November 25, 2003

Examiner: To be assigned

For: Kunitz-Type Sequences and Polypeptides

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. US Patent No. 6,180,607
2. WO 89/10374 A1
3. Auer et al., Acta Neurochirurgica, Vol. 49, pages 207-217 (1979)


4. Bidstrup et al., J. Thorac Cardiovasc Surg, Vol. 97, pages 364-372 (1989)
5. Delaria et al., The Journal of Biological Chemistry, Vol. 272, No. 18, pages 12209-12214 (1997)
6. Dennis et al., The Journal of Biological Chemistry, Vol. 270, No. 43, pages 25411-25417 (1995)
7. Glaser et al., Verhandlungen der Deutschen Gesellschaft für Innere Medizin, Vol. 78, pages 1612-1614 (1972) (translation)
8. McMichan et al., Circulatory Shock, Vol. 9, pages 107-116 (1982)
9. Petersen et al., Eur. J. Biochem., Vol. 235, pages 310-316 (1996)
10. Petersen et al., Biochemistry, Vol. 35, pages 266-272 (1996)
11. Schneider, Arzneim-Forsch. (Drug Res.), Vol. 26 No. 8, pages 1606-1610 (1976) (translation)
12. Sher et al., American Journal of Obstetrics and Gynecology, Vol. 129, No. 2, pages 164-170 (1977)
13. Sprecher et al., Proc. Natl. Acad. Sci. USA, Vol. 91, pages 3353-3357 (1994)
14. Trapnell et al., Br. J. Surg., Vol. 61, pages 177-182 (1974)
15. van Oeveren et al., Ann Thorac Surg, Vol. 44, pages 640-645 (1987)
16. Wagner et al., Biochemical and Biophysical Research Communications, Vol. 186, No. 2, pages 1138-1145 (1992)
17. Wenzel et al., Angew. Chem. Int. Ed. Engl., Vol. 20, No. 3, pages 295-296 (1981)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: March 31, 2004

Respectfully submitted,



Len S. Smith, Reg. No. 43,139
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

FORM PTO-1449
(Rev. 6-2)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6297.204-US

Serial No. 10/721,961

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Applicant Jorgensen et. al.

(Use several sheets if necessary)

Filing Date November 25, 2003

Group To be assigned

U.S. PATENT DOCUMENTS

INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,180,607 B1	1/30/01	Davies et al.	514	12	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 89/10374 A1	11/2/89	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Auer et al., Acta Neurochirurgica, Vol. 49, pages 207-217 (1979)
		Bidstrup et al., J. Thorac Cardiovasc Surg, Vol. 97, pages 364-372 (1989)
		Delaria et al., The Journal of Biological Chemistry, Vol. 272, No. 18, pages 12209-12214 (1997)
		Dennis et al., The Journal of Biological Chemistry, Vol. 270, No. 43, pages 25411-25417 (1995)
		Glaser et al., Verhandlungen der Deutschen Gesellschaft für Innere Medizin, Vo. 78, pages 1612-1614 (1972) (translation)
		McMichan et al., Circulatory Shock, Vol. 9, pages 107-116 (1982)
		Petersen et al., Eur. J. Biochem., Vol. 235, pages 310-316 (1996)
		Petersen et al., Biochemistry, Vol. 35, pages 266-272 (1996)
		Schneider, Arzneim-Forsch. (Drug Res.), Vol. 26 No. 8, pages 1606-1610 (1976) (translation)
		Sher et al., American Journal of Obstetrics and Gynecology, Vol. 129, No. 2, pages 164-170 (1977)
		Sprecher et al., Proc. Natl. Acad. Sci. USA, Vol. 91, pages 3353-3357 (1994)
		Trapnell et al., Br. J. Surg., Vol. 61, pages 177-182 (1974)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6297.204-US

Serial No. 10/721,961

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant Jorgensen et. al.

Filing Date November 25, 2003

Group To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			van Oeveren et al., Ann Thorac Surg, Vol. 44, pages 640-645 (1987)
			Wagner et al., Biochemical and Biophysical Research Communications, Vol. 186, No. 2, pages 1138-1145 (1992)
			Wenzel et al., Angew. Chem. Int. Ed. Engl., Vol. 20, No. 3, pages 295-296 (1981)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.